GPNMB Serum levels in patients with acute coronary syndrome: an exploratory study

GPNMB Serum levels in patients with acute coronary syndrome: an exploratory study - ProKoro1

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022900

Enrollment

Registered

2020-08-21

Start date

2021-04-18

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I21

Interventions

Group 1: GPNMB serum level 0, 1, 2, 3, 7 und 30 after akute Myocardial Infarction Group 2: GPNMB serum levels at day 0, 7 und 30 in healthy volunteers

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Willingness to participate in the study (informed consent) - Heart attack: clinically, laboratory chemically and serologically confirmed (study arm only)

Exclusion criteria

Exclusion criteria: - Cardiomyopathies, severe Vitien (heart valve diseases) - Pulmonary embolisms - Myocarditis - Oncological-immunological diseases - Dementia patients - Participation in further studies or clinical trials

Design outcomes

Primary

Measure	Time frame
The primary objective of the study is to measure the GPNMB serum concentration in healthy volunteers and in patients with acute coronary syndrome on day 7.	—

Secondary

Measure	Time frame
- The difference in serum concentration GPNMB on day 7 in heart attack patients vs. controls - The correlation of serum GPNMB to CK, hs-TnT, NT-ProBNP - The correlation of serum GPNMB to cardiac remodeling evaluated by echocardiographic examination	—

Countries

Germany

Contacts

Public ContactCemil Özcelik

Klinik Helios Klinikum Emil von Behring GmbH, Berlin

Cemil.Oezcelik@helios-gesundheit.de+49 30 8102-1943

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026